Vanda Pharmaceuticals is showcasing Bysanti at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Bysanti is a brand-new NCE just approved in 2026 — this is a launch conference for Vanda. They'll be introducing psychiatrists to a new antipsychotic option with patent protection through 2044. The Phase 3 TRD-MDD trial readout (end of 2026) adds a forward-looking element. Commercial availability Q3 2026.
Ask about: What differentiates Bysanti from Fanapt and from the broader atypical class?; launch strategy and commercial availability timeline (Q3 2026); TRD-MDD Phase 3 trial design and expected readout; prescriber education strategy; how they compete against Cobenfy (novel MOA), Caplyta, and Vraylar in a crowded space. Brand-new NCE launches at APA are rare — this is a high-attention moment.
Brand-new NCE needs rapid RWE from day one. VoiceVitals provides continuous objective monitoring for bipolar and schizophrenia patients starting Bysanti — data that starts generating the real-world evidence base immediately. For TRD-MDD Phase 3, ePRO+ with multimodal behavioral assessment can enrich endpoints. 2044 patent = long runway for an evidence-generation partnership.
Set up a follow-up with Vanda Pharmaceuticals's team and Videra Health.
Email Ryan Roberts →